Company intelligence / Profile preview
ImunoTera
São Paulo, São Paulo, Brazilklinikaimunotera.lt ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
ImunoTera’s lead product TERAH‑7 has shown promising results in animal models and early patient studies. In a small experimental clinical study using autologous dendritic cell therapy activated with the recombinant protein, some patients with CIN experienced complete regression of lesions without surgery. The molecule also shows synergism with chemotherapy in preclinical models. Non-clinical toxicity studies are ongoing as of 2025; regulatory steps toward formal clinical trials are planned
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Recombinant protein therapeuticsDNA and RNA-based immunotherapiesCell therapy (dendritic cell activation)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Biotechtown accelerator/investorUniversity of São Paulo/Biomedical Sciences Institute collaborations
Beyond the preview
Go deeper on ImunoTera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImunoTera.